A conceivable hypothesis would be that RA individuals which showed low levels of activation of relevant downstream signalling proteins in disease tissue would be less likely to respond to drugs which target proteins or cell surface receptors associated with targeting those pathways. The gene discussed is CD177; the disease is rheumatoid arthritis.